National and Kapodistrian University of Athens
Nickel hypersensitivity after transcatheter patent foramen ovale (PFO) closure
Abstract
dc:descriptionBackground: Cryptogenic strokes account for about 25% to 30% of ischemic strokes. A patent foramen ovale (PFO) is present in about 25% of the general population and has been implicated in paradoxical embolism. Although the lifetime stroke risk attributable to PFO is low, transcatheter PFO closure has demonstrated efficacy in secondary stroke prevention. Randomized trials have shown significant reductions in recurrent stroke risk compared with antithrombotic treatment alone. Nickel-containing devices, such as the Amplatzer PFO Occluder and GSO, are used for transcatheter PFO closure. However, the impact of nickel hypersensitivity on postprocedural outcomes remains poorly understood. This study aimed to evaluate the risk of adverse events in patients with nickel hypersensitivity undergoing PFO closure. Methods: This was a prospective, double-blind, randomized study enrolling patients with cryptogenic stroke and PFO-related ischemic stroke to receive either the Amplatzer or GSO device. Nickel hypersensitivity was assessed using skin patch testing. The primary end point was the incidence of device syndrome, a composite of patient-reported symptoms (chest pain, palpitations, migraines, dyspnea, and rash). Additionally, device- and sex-based analyses were performed, as well as investigation of sensitization following the PFO closure.Results: Of the 96 patients, 28 (29.2%) had nickel hypersensitivity. The incidence of device syndrome was significantly higher in patients with nickel hypersensitivity compared with those without (71.4% versus 20.6%, p < 0.001). Specifically, new-onset or worsening migraines and palpitations were more frequent in nickel-hypersensitive patients. No significant differences were observed in documented arrhythmias, bleeding, or stroke. Multivariable analysis showed that nickel hypersensitivity was associated with a 10.5-fold increase in the odds of device syndrome (adjusted odds ratio, 10.53 [95% CI, 3.17–35.00]; p < 0.001). The incidence of device syndrome was similar for both devices. Furthermore, the new-onset or worsening migraines (15.6% vs 0.0%, p = 0.003) were significantly more frequent in female than male patients. In female patients, device syndrome was observed in 78.3% of those with nickel hypersensitivity, compared with 18.2% of those without (p < 0.001). Palpitations occurred in 52.2% of female patients with nickel hypersensitivity, significantly more than 13.6% without (p = 0.006). Conclusions: Patients with nickel hypersensitivity are at significantly higher risk of developing device syndrome after PFO closure. Both the Amplatzer and GSO devices demonstrated comparable safety and efficacy in this population. These findings highlight the need for further research to optimize device selection and improve outcomes in nickel-hypersensitive patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Apostolos, Anastasios
- Αποστολός, Αναστάσιος
Subjects
dc:subject × 17- Νικέλιο
- Ανοικτό ωοειδές τρήμα
- Υπερευαισθησία επιβραδυνόμενου τύπου
- Αλλεργία
- Nickel
- Allergy
- Patent foramen ovale
- Contact hypersensitivity response
- Delayed hypersensitivity reaction
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Καρδιολογία και Καρδιοαγγειακά νοσήματα
- Δερματολογία
- Clinical Medicine
- Medical and Health Sciences
- Cardiology and Cardiovascular Medicine
- Dermatology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61032